Results 131 to 140 of about 70,621 (279)

Prophylactic Evidence of MSCs-Derived Exosomes in Doxorubicin/Trastuzumab-Induced Cardiotoxicity: Beyond Mechanistic Target of NRG-1/Erb Signaling Pathway [PDF]

, 2022
Nesrine Ebrahim, Hajir A. Al Saihati, Ola Mostafa, Amira Hassouna, Sameh Abdulsamea, Eman El-Gebaly, Nashwa H. Aborayah, Dina Sabry, Mohamed El‐Sherbiny, Abdelmonem G. Madboly, Noha I. Hussien, Raja El Hasnaoui- Saadani, Hasnaa Ali Ebrahim, Omnia A. Badr, Nehal M. Elsherbiny, Rabab F. Salim   +15 more
openalex   +1 more source

Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer

MedComm, Volume 7, Issue 4, April 2026.
This phase II trial evaluated the efficacy and safety of niraparib combined with HX008 in metastatic breast cancer (MBC) patients with germline DNA damage response (DDR) gene mutations. This chemotherapy‐free regimen demonstrates promising efficacy and a tolerable safety profile in MBC patients with germline DDR mutations, providing a novel therapeutic
Jian Zhang, Yiqun Du, Yanchun Meng, Yizi Jin, Mingxi Lin, Xuchen Shao, Xiaojun Liu, Yuxin Mu, Yun Liu, Zhen Hu   +9 more
wiley   +1 more source

Characterization of high affinity IgM and IgG monoclonal antibodies against norovirus variants GII.4 and GII.17

Protein Science, Volume 35, Issue 4, April 2026.
Abstract Human noroviruses are a leading cause of acute gastroenteritis worldwide, yet the molecular principles governing antibody recognition of their highly repetitive capsid remain poorly understood. Here, we immunized mice with virus‐like particles (VLPs) from the pandemic GII.4 strain and the emergent GII.17 strain, generating monoclonal IgM and ...
Jumpei Tagawa, Saeko Yanaka, Yuri Kato, Akitsu Masuda, Jae Man Lee, Akinobu Senoo, Kosuke Oyama, Takayuki Uchihashi, Motohiro Nishida, Takahiro Kusakabe, Jose M. M. Caaveiro   +10 more
wiley   +1 more source

Synthesis and Biological Evaluation of Homogeneous Thiol‐Linked NHC*‐Au‐Albumin and ‐Trastuzumab Bioconjugates [PDF]

, 2018
María João Matos, Carlos Labão‐Almeida, Claire T. Sayers, Oyinlola Dada, Matthias Tacke, Gonçalo J. L. Bernardes   +5 more
openalex   +1 more source

Label-Free, Rapid and Facile Gold-Nanoparticles-Based Assay as a Potential Spectroscopic Tool for Trastuzumab Quantification [PDF]

, 2021
Ahmed Alsadig, Hendrik Vondracek, Paolo Pengo, Lucia Pasquato, Paola Posocco, Pietro Parisse, Loredana Casalis   +6 more
openalex   +1 more source

Safety and Efficacy Assessment of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2‐Positive Unresectable Locally Advanced or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane: An Open‐Label, Single‐Arm, Phase IV Study

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 240-250, April 2026.
A phase IV, single‐arm, open‐label, multicenter study assessing the safety and efficacy of trastuzumab emtansine in Indian patients for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive unresectable locally advanced or metastatic breast cancer who received prior treatment with trastuzumab and a taxane.
Sudeep Gupta, Manish Singhal, Shona Nag, Waseem Abbas, Dinesh Chandra Doval, Hari Goyal, Chirag Shah, Ashish Singh, Radheshyam Naik, Nitesh Rohatgi, Poonam Patil, Shyam Aggarwal, Vinod Raina, Vaibhav Watts   +13 more
wiley   +1 more source

The Association Between Circadian Disruption in Core Body Temperature Rhythm and Post‐Chemotherapy Sleep Disturbances in Breast Cancer Survivors

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT Sleep disturbance is a common symptom experienced by approximately 70% of breast cancer survivors and persists after the conclusion of chemotherapy. This study aimed to quantify the circadian disruption of the core body temperature (CBT) rhythm and its correlation with sleep disturbance following chemotherapy.
Joon Sung Shin, Sanghyup Jung, Geun Hui Won, Sun Hyung Lee, Jaehyun Kim, Saim Jung, Chan‐Woo Yeom, Kwang‐Min Lee, Kyung‐Lak Son, Jang‐il Kim, Sook Young Jeon, Han‐Byoel Lee, Bong‐Jin Hahm   +12 more
wiley   +1 more source

Early Detection of Trastuzumab and Radiation Induced Cardiotoxicity in Mice Using Echocardiography and PET/CT [PDF]

, 2020
P. Yi, Hanyue Li, Jun Su, Lu Cao, Chundi Xu, M. Li, J.Y. Chen   +6 more
openalex   +1 more source

Meta-analysis of Clinical Efficacy and Safety of Pertuzumab and Trastuzumab Combined Therapy in HER-2 Positive Breast Cancer [PDF]

, 2023
Xiaoyu Zhang, Hui Zhang, Hengle Zhang, Yulai Yin, Yue Ren, Xiaoning Kang, Lijun Jin, Jie Bai   +7 more
openalex   +1 more source

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source